AAPL   277.99 (+1.63%)
FB   189.64 (-0.06%)
MSFT   162.23 (+2.55%)
GOOGL   1,306.75 (-0.62%)
AMZN   1,872.12 (-0.65%)
NVDA   271.85 (+7.62%)
MU   52.82 (+4.43%)
AMD   45.36 (+3.07%)
T   35.12 (-1.71%)
ACB   1.38 (-4.84%)
NFLX   370.83 (-0.24%)
BAC   28.49 (-2.20%)
GILD   69.27 (-4.67%)
DIS   116.36 (-1.42%)
AAPL   277.99 (+1.63%)
FB   189.64 (-0.06%)
MSFT   162.23 (+2.55%)
GOOGL   1,306.75 (-0.62%)
AMZN   1,872.12 (-0.65%)
NVDA   271.85 (+7.62%)
MU   52.82 (+4.43%)
AMD   45.36 (+3.07%)
T   35.12 (-1.71%)
ACB   1.38 (-4.84%)
NFLX   370.83 (-0.24%)
BAC   28.49 (-2.20%)
GILD   69.27 (-4.67%)
DIS   116.36 (-1.42%)
AAPL   277.99 (+1.63%)
FB   189.64 (-0.06%)
MSFT   162.23 (+2.55%)
GOOGL   1,306.75 (-0.62%)
AMZN   1,872.12 (-0.65%)
NVDA   271.85 (+7.62%)
MU   52.82 (+4.43%)
AMD   45.36 (+3.07%)
T   35.12 (-1.71%)
ACB   1.38 (-4.84%)
NFLX   370.83 (-0.24%)
BAC   28.49 (-2.20%)
GILD   69.27 (-4.67%)
DIS   116.36 (-1.42%)
AAPL   277.99 (+1.63%)
FB   189.64 (-0.06%)
MSFT   162.23 (+2.55%)
GOOGL   1,306.75 (-0.62%)
AMZN   1,872.12 (-0.65%)
NVDA   271.85 (+7.62%)
MU   52.82 (+4.43%)
AMD   45.36 (+3.07%)
T   35.12 (-1.71%)
ACB   1.38 (-4.84%)
NFLX   370.83 (-0.24%)
BAC   28.49 (-2.20%)
GILD   69.27 (-4.67%)
DIS   116.36 (-1.42%)
Log in

NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

$52.05
-2.33 (-4.28 %)
(As of 02/28/2020 11:47 AM ET)
Today's Range
$51.64
Now: $52.05
$54.62
50-Day Range
$54.38
MA: $68.51
$82.22
52-Week Range
$54.32
Now: $52.05
$102.98
Volume15,618 shs
Average Volume735,373 shs
Market Capitalization$2.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.65
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BPMC
CUSIPN/A
Phone617-374-7580

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$66.51 million
Book Value$8.59 per share

Profitability

Net Income$-347,690,000.00
Net Margins-522.75%

Miscellaneous

Employees217
Market Cap$2.81 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.


Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Corp (NASDAQ:BPMC) announced its quarterly earnings results on Thursday, February, 13th. The biotechnology company reported ($1.35) EPS for the quarter, beating the Zacks' consensus estimate of ($1.71) by $0.36. The biotechnology company earned $51.53 million during the quarter, compared to analyst estimates of $26 million. Blueprint Medicines had a negative net margin of 522.75% and a negative return on equity of 72.52%. Blueprint Medicines's quarterly revenue was up 4888.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.83) EPS. View Blueprint Medicines' Earnings History.

When is Blueprint Medicines' next earnings date?

Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Blueprint Medicines.

What price target have analysts set for BPMC?

12 equities research analysts have issued twelve-month price objectives for Blueprint Medicines' stock. Their forecasts range from $70.00 to $125.00. On average, they expect Blueprint Medicines' share price to reach $104.08 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.

What is the consensus analysts' recommendation for Blueprint Medicines?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.

Has Blueprint Medicines been receiving favorable news coverage?

Press coverage about BPMC stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Blueprint Medicines earned a news impact score of -4.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Blueprint Medicines.

Who are some of Blueprint Medicines' key competitors?

What other stocks do shareholders of Blueprint Medicines own?

Who are Blueprint Medicines' key executives?

Blueprint Medicines' management team includes the folowing people:
  • Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 48)
  • Mr. Alexis A. Borisy, Co-Founder & Director (Age 47)
  • Mr. Michael Landsittel, Chief Financial Officer (Age 47)
  • Ms. Kathryn Haviland, Chief Operating Officer (Age 43)
  • Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 56)

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Cadian Capital Management LP (4.00%), State Street Corp (3.81%), Alliancebernstein L.P. (2.08%), Westfield Capital Management Co. LP (1.57%) and Eagle Asset Management Inc. (1.55%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.

Which institutional investors are selling Blueprint Medicines stock?

BPMC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Pictet Asset Management Ltd., Perceptive Advisors LLC, BVF Inc. IL, Victory Capital Management Inc., Westfield Capital Management Co. LP, Victory Capital Management Inc. and Spark Investment Management LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.

Which institutional investors are buying Blueprint Medicines stock?

BPMC stock was purchased by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Credit Suisse AG, Barclays PLC, Alliancebernstein L.P., Jane Street Group LLC and Sectoral Asset Management Inc. View Insider Buying and Selling for Blueprint Medicines.

How do I buy shares of Blueprint Medicines?

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $52.05.

How big of a company is Blueprint Medicines?

Blueprint Medicines has a market capitalization of $2.81 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe.View Additional Information About Blueprint Medicines.

What is Blueprint Medicines' official website?

The official website for Blueprint Medicines is http://www.blueprintmedicines.com/.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]


MarketBeat Community Rating for Blueprint Medicines (NASDAQ BPMC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  417 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  708
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: VIX - Volatility Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel